Overview
Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare bone marrow failure syndrome characterized by severe thrombocytopenia due to a deficiency in megakaryocyte production, often presenting shortly after birth 1.Diagnosis
Isolated thrombocytopenia at birth or early infancy
Bone marrow examination showing markedly reduced or absent megakaryocytes 1
Genetic testing may reveal mutations in genes like CDC25C or JAK2 1Management
First-line treatment: Hematopoietic stem cell transplantation (HSCT) is curative 1
Reduced intensity conditioning (RIC) regimen: Use of alemtuzumab, fludarabine, and melphalan can be effective with acceptable morbidity 1
Monitoring: Close monitoring for engraftment, typically neutrophil engraftment by day +12 and platelet engraftment by day +29 1Special Populations
Pediatrics: RIC HSCT appears feasible and well-tolerated in young children, as evidenced by successful outcomes in a seven-month-old patient 1Key Recommendations
Hematopoietic stem cell transplantation should be considered the primary curative approach for CAMT (Evidence: Strong 1)
Reduced intensity conditioning regimens, including alemtuzumab, fludarabine, and melphalan, can be safely utilized in pediatric patients (Evidence: Moderate 1)
Monitor for early signs of engraftment post-transplant, with neutrophil engraftment expected by day +12 and platelet engraftment by day +29 (Evidence: Expert opinion 1)References
1 Woods G, Bajwa RP, Rose MJ. Reduced intensity transplantation for congenital amegakaryocytic thrombocytopenia: report of a case and review of the literature. Pediatric transplantation 2014. link